Surgical treatment of pancreatic cancer. The United States experience
- PMID: 1720800
- DOI: 10.1007/BF02925591
Surgical treatment of pancreatic cancer. The United States experience
Abstract
About 28,000 new cases of pancreatic cancer are diagnosed yearly in the United States. The diagnosis is now made up to two months more quickly than just a few years ago, but this has had no impact on survival. In most institutions, 20-25% of patients have resectable lesions. The standard operation is still the Whipple pancreaticoduodenectomy, but many surgeons now use the pylorus preserving modification of that procedure. The operative mortality rate has fallen to less than 5%. The five-year survival rate after a resection for attempted cure is about 9%. Palliation requires cholecysto(docho)jejunostomy and gastrojejunostomy, which is often done prophylactically. The operative mortality rate in patients undergoing palliation is less than 10% (recent UCLA experience), and the average survival is seven months.
Similar articles
-
[Palliative treatment of pancreatic adenocarcinoma].Ann Ital Chir. 1997 Sep-Oct;68(5):635-41. Ann Ital Chir. 1997. PMID: 9577040 Review. Italian.
-
Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampullary adenocarcinoma.Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1060-6. doi: 10.1016/j.ijrobp.2005.03.036. Epub 2005 Jun 22. Int J Radiat Oncol Biol Phys. 2005. PMID: 15978737
-
Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer?Ann Surg. 1996 Jun;223(6):718-25; discussion 725-8. doi: 10.1097/00000658-199606000-00010. Ann Surg. 1996. PMID: 8645045 Free PMC article.
-
Pylorus-preserving pancreaticoduodenectomy versus conventional whipple operation.World J Surg. 1999 Sep;23(9):920-5. doi: 10.1007/s002689900600. World J Surg. 1999. PMID: 10449821
-
Pylorus-preserving pancreaticoduodenectomy.Surg Oncol Clin N Am. 1998 Jan;7(1):143-56. Surg Oncol Clin N Am. 1998. PMID: 9443992 Review.
Cited by
-
Magnetic resonance angiography in the resectability assessment of suspected pancreatic tumours.Eur Radiol. 1997;7(5):649-53. doi: 10.1007/BF02742919. Eur Radiol. 1997. PMID: 9166560
-
Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial.Surg Today. 2008;38(11):1021-8. doi: 10.1007/s00595-007-3745-8. Epub 2008 Oct 29. Surg Today. 2008. PMID: 18958561 Clinical Trial.
-
Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin.Jpn J Cancer Res. 1998 Sep;89(9):963-9. doi: 10.1111/j.1349-7006.1998.tb00655.x. Jpn J Cancer Res. 1998. PMID: 9818033 Free PMC article.
-
p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb.Ann Surg. 2002 Jan;235(1):51-9. doi: 10.1097/00000658-200201000-00007. Ann Surg. 2002. PMID: 11753042 Free PMC article.
-
Aggressive surgery for pancreatic duct cell cancer: feasibility, validity, limitations.World J Surg. 1995 Jul-Aug;19(4):653-9; discussion 660. doi: 10.1007/BF00294750. World J Surg. 1995. PMID: 7676716 Clinical Trial.
References
MeSH terms
LinkOut - more resources
Medical